- In January 2025, MedPharm announced the successful completion of clinical trials for its novel hydrogel-based topical antifungal treatment. The hydrogel is designed to deliver high concentrations of active ingredients directly to affected areas, offering improved outcomes in the treatment of fungal skin infections such as athlete’s foot and ringworm
- In October 2024, Hisamitsu Pharmaceutical announced the commencement of clinical development for its transdermal nonsteroidal pain treatment, HP-3150, in the U.S. This diclofenac sodium-based patch aims to provide sustained pain relief for chronic lower back pain through once-daily application, leveraging the company's Transdermal Drug Delivery System (TDDS) technology. The company plans to initiate a clinical pharmacology study in fiscal year 2025, followed by a Phase III clinical study in fiscal year 2026
- In March 2024, Hisamitsu America marked the 90th anniversary of its flagship product, Salonpas, the world's No. 1 brand of over-the-counter (OTC) topical analgesic patches. The company reported record sales across various channels, including food, drug, mass, club, and e-commerce, highlighting the enduring popularity and effectiveness of Salonpas in pain relief
- In December 2024, the Indian pharmaceutical industry is poised for significant transformation, with technological advancements such as artificial intelligence (AI) and machine learning revolutionizing drug discovery, manufacturing, and patient care. The industry aims to focus on research excellence and innovation, positioning India as a global hub for high-quality, affordable pharmaceuticals
- In February 2021, Almirall S.A., a worldwide biopharmaceutical company pioneering a new standard in topical medicines for autoimmune and chronic inflammatory disorders, announced that MC2 Therapeutics has granted Almirall exclusive European rights to market Wynzora Cream for plaque psoriasis therapy
